CEBP CTRC-AACR San Antonio Breast Cancer Symposium 2008 Conference on Cancer Prevention - Washington, D.C.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strickland, P. T.
Right arrow Articles by Dipple, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strickland, P. T.
Right arrow Articles by Dipple, A.

Cancer Epidemiology Biomarkers & Prevention, Vol 2, Issue 6 607-619, Copyright © 1993 by American Association for Cancer Research


ARTICLES

Methodologies for measuring carcinogen adducts in humans

PT Strickland, MN Routledge and A Dipple
Department of Environmental Health Sciences, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland 21205.

In summary, although some of the more optimistic aspirations for human biomonitoring studies envisaged a decade ago have not been realized thus far, some considerable advances have been made. The examples cited above indicate that the feasibility of biomonitoring has been clearly established. In addition, they demonstrate the need for preliminary biomarker testing and validation through transitional studies prior to their field application. In the next decade of research into carcinogen adducts in humans, continued improvements in the reproducibility and specificity of assays for DNA adducts will be needed. Perhaps the increasing use of hybrid methodologies to concentrate adducts followed by specific chemical analyses will allow such adducts to be monitored more precisely. Of course, further basic research into the mechanisms of carcinogenesis will allow the measurement of specific novel markers which are more closely tied to the disease endpoint than adducts. The development of new assays for determining metabolic phenotypes and genotypes relevant to carcinogenesis should improve our estimates of susceptibility (46-48). Such new approaches along with the sustained improvement of current assays will allow molecular approaches to continue to enrich cancer epidemiology in the future.


This article has been cited by other articles:


Home page
CarcinogenesisHome page
D. H. Phillips
Smoking-related DNA and protein adducts in human tissues
Carcinogenesis, December 1, 2002; 23(12): 1979 - 2004.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
A. G. Zavala, T. Lancaster, J. D. Groopman, P. T. Strickland, and S. Chandrasegaran
Phage display of ScFv peptides recognizing the thymidine(6-4)thymidine photoproduct
Nucleic Acids Res., April 1, 2000; 28(7): e24 - e24.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. C. Poirier, R. M. Santella, and A. Weston
Carcinogen macromolecular adducts and their measurement
Carcinogenesis, March 1, 2000; 21(3): 353 - 359.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1993 by the American Association for Cancer Research.